Selected research
Industry Research
Advanced Biopharmaceutical Therapies Industry Research Report 2026
Market perspective
The global Advanced Biopharmaceutical Therapies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Advanced Biopharmaceutical Therapies market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Advanced Biopharmaceutical Therapies market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Advanced Biopharmaceutical Therapies market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Advanced Biopharmaceutical Therapies include Lonza, Thermo Fisher Scientific, Catalent, Samsung Biologics, AGC Biologics, WuXi AppTec, Charles River Laboratories, Cytiva and Rentschler Biopharma, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Advanced Biopharmaceutical Therapies market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Advanced Biopharmaceutical Therapies.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Advanced Biopharmaceutical Therapies Market by Company
Lonza
Thermo Fisher Scientific
Catalent
Samsung Biologics
AGC Biologics
WuXi AppTec
Charles River Laboratories
Cytiva
Rentschler Biopharma
Oxford Biomedica
OmniaBio
Genezen
Cellipont Bioservices
VectorBuilder
Viralgen
ABL Europe
Advanced Biopharmaceutical Therapies Segment by Type
Cell Therapy Services
Gene Therapy Services
Nucleic Acid Therapy Services
Advanced Biopharmaceutical Therapies Segment by Application
Biopharmaceutical Industry
Research and Education Institutions
Others
Advanced Biopharmaceutical Therapies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Advanced Biopharmaceutical Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Advanced Biopharmaceutical Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Advanced Biopharmaceutical Therapies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Advanced Biopharmaceutical Therapies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cell Therapy Services
- Gene Therapy Services
- Nucleic Acid Therapy Services
Applications
- Biopharmaceutical Industry
- Research and Education Institutions
- Others
Companies covered
- Lonza
- Thermo Fisher Scientific
- Catalent
- Samsung Biologics
- AGC Biologics
- WuXi AppTec
- Charles River Laboratories
- Cytiva
- Rentschler Biopharma
- Oxford Biomedica
- OmniaBio
- Genezen
- Cellipont Bioservices
- VectorBuilder
- Viralgen
- ABL Europe
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Advanced Biopharmaceutical Therapies by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cell Therapy Services
- 2.2.3 Gene Therapy Services
- 2.2.4 Nucleic Acid Therapy Services
- 2.3 Advanced Biopharmaceutical Therapies by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Biopharmaceutical Industry
- 2.3.3 Research and Education Institutions
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Advanced Biopharmaceutical Therapies Breakdown Data by Type
- 3.1 Global Advanced Biopharmaceutical Therapies Historic Market Size by Type (2021-2026)
- 3.2 Global Advanced Biopharmaceutical Therapies Forecasted Market Size by Type (2027-2032)
4 Advanced Biopharmaceutical Therapies Breakdown Data by Application
- 4.1 Global Advanced Biopharmaceutical Therapies Historic Market Size by Application (2021-2026)
- 4.2 Global Advanced Biopharmaceutical Therapies Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Advanced Biopharmaceutical Therapies Market Perspective (2021-2032)
- 5.2 Global Advanced Biopharmaceutical Therapies Growth Trends by Region
- 5.2.1 Global Advanced Biopharmaceutical Therapies Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Advanced Biopharmaceutical Therapies Historic Market Size by Region (2021-2026)
- 5.2.3 Advanced Biopharmaceutical Therapies Forecasted Market Size by Region (2027-2032)
- 5.3 Advanced Biopharmaceutical Therapies Market Dynamics
- 5.3.1 Advanced Biopharmaceutical Therapies Industry Trends
- 5.3.2 Advanced Biopharmaceutical Therapies Market Drivers
- 5.3.3 Advanced Biopharmaceutical Therapies Market Challenges
- 5.3.4 Advanced Biopharmaceutical Therapies Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Advanced Biopharmaceutical Therapies Players by Revenue
- 6.1.1 Global Top Advanced Biopharmaceutical Therapies Players by Revenue (2021-2026)
- 6.1.2 Global Advanced Biopharmaceutical Therapies Revenue Market Share by Players (2021-2026)
- 6.2 Global Advanced Biopharmaceutical Therapies Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Advanced Biopharmaceutical Therapies Head Office and Area Served
- 6.4 Global Advanced Biopharmaceutical Therapies Players, Product Type & Application
- 6.5 Global Advanced Biopharmaceutical Therapies Manufacturers Established Date
- 6.6 Global Advanced Biopharmaceutical Therapies Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Advanced Biopharmaceutical Therapies Market Size (2021-2032)
- 7.2 North America Advanced Biopharmaceutical Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Advanced Biopharmaceutical Therapies Market Size by Country (2021-2026)
- 7.4 North America Advanced Biopharmaceutical Therapies Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Advanced Biopharmaceutical Therapies Market Size (2021-2032)
- 8.2 Europe Advanced Biopharmaceutical Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Advanced Biopharmaceutical Therapies Market Size by Country (2021-2026)
- 8.4 Europe Advanced Biopharmaceutical Therapies Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Advanced Biopharmaceutical Therapies Market Size (2021-2032)
- 9.2 Asia-Pacific Advanced Biopharmaceutical Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Advanced Biopharmaceutical Therapies Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Advanced Biopharmaceutical Therapies Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Advanced Biopharmaceutical Therapies Market Size (2021-2032)
- 10.2 South America Advanced Biopharmaceutical Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Advanced Biopharmaceutical Therapies Market Size by Country (2021-2026)
- 10.4 South America Advanced Biopharmaceutical Therapies Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Advanced Biopharmaceutical Therapies Market Size (2021-2032)
- 11.2 Middle East & Africa Advanced Biopharmaceutical Therapies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Advanced Biopharmaceutical Therapies Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Advanced Biopharmaceutical Therapies Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Lonza
- 12.1.1 Lonza Company Information
- 12.1.2 Lonza Business Overview
- 12.1.3 Lonza Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.1.4 Lonza Advanced Biopharmaceutical Therapies Product Portfolio
- 12.1.5 Lonza Recent Developments
- 12.2 Thermo Fisher Scientific
- 12.2.1 Thermo Fisher Scientific Company Information
- 12.2.2 Thermo Fisher Scientific Business Overview
- 12.2.3 Thermo Fisher Scientific Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.2.4 Thermo Fisher Scientific Advanced Biopharmaceutical Therapies Product Portfolio
- 12.2.5 Thermo Fisher Scientific Recent Developments
- 12.3 Catalent
- 12.3.1 Catalent Company Information
- 12.3.2 Catalent Business Overview
- 12.3.3 Catalent Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.3.4 Catalent Advanced Biopharmaceutical Therapies Product Portfolio
- 12.3.5 Catalent Recent Developments
- 12.4 Samsung Biologics
- 12.4.1 Samsung Biologics Company Information
- 12.4.2 Samsung Biologics Business Overview
- 12.4.3 Samsung Biologics Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.4.4 Samsung Biologics Advanced Biopharmaceutical Therapies Product Portfolio
- 12.4.5 Samsung Biologics Recent Developments
- 12.5 AGC Biologics
- 12.5.1 AGC Biologics Company Information
- 12.5.2 AGC Biologics Business Overview
- 12.5.3 AGC Biologics Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.5.4 AGC Biologics Advanced Biopharmaceutical Therapies Product Portfolio
- 12.5.5 AGC Biologics Recent Developments
- 12.6 WuXi AppTec
- 12.6.1 WuXi AppTec Company Information
- 12.6.2 WuXi AppTec Business Overview
- 12.6.3 WuXi AppTec Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.6.4 WuXi AppTec Advanced Biopharmaceutical Therapies Product Portfolio
- 12.6.5 WuXi AppTec Recent Developments
- 12.7 Charles River Laboratories
- 12.7.1 Charles River Laboratories Company Information
- 12.7.2 Charles River Laboratories Business Overview
- 12.7.3 Charles River Laboratories Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.7.4 Charles River Laboratories Advanced Biopharmaceutical Therapies Product Portfolio
- 12.7.5 Charles River Laboratories Recent Developments
- 12.8 Cytiva
- 12.8.1 Cytiva Company Information
- 12.8.2 Cytiva Business Overview
- 12.8.3 Cytiva Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.8.4 Cytiva Advanced Biopharmaceutical Therapies Product Portfolio
- 12.8.5 Cytiva Recent Developments
- 12.9 Rentschler Biopharma
- 12.9.1 Rentschler Biopharma Company Information
- 12.9.2 Rentschler Biopharma Business Overview
- 12.9.3 Rentschler Biopharma Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.9.4 Rentschler Biopharma Advanced Biopharmaceutical Therapies Product Portfolio
- 12.9.5 Rentschler Biopharma Recent Developments
- 12.10 Oxford Biomedica
- 12.10.1 Oxford Biomedica Company Information
- 12.10.2 Oxford Biomedica Business Overview
- 12.10.3 Oxford Biomedica Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.10.4 Oxford Biomedica Advanced Biopharmaceutical Therapies Product Portfolio
- 12.10.5 Oxford Biomedica Recent Developments
- 12.11 OmniaBio
- 12.11.1 OmniaBio Company Information
- 12.11.2 OmniaBio Business Overview
- 12.11.3 OmniaBio Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.11.4 OmniaBio Advanced Biopharmaceutical Therapies Product Portfolio
- 12.11.5 OmniaBio Recent Developments
- 12.12 Genezen
- 12.12.1 Genezen Company Information
- 12.12.2 Genezen Business Overview
- 12.12.3 Genezen Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.12.4 Genezen Advanced Biopharmaceutical Therapies Product Portfolio
- 12.12.5 Genezen Recent Developments
- 12.13 Cellipont Bioservices
- 12.13.1 Cellipont Bioservices Company Information
- 12.13.2 Cellipont Bioservices Business Overview
- 12.13.3 Cellipont Bioservices Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.13.4 Cellipont Bioservices Advanced Biopharmaceutical Therapies Product Portfolio
- 12.13.5 Cellipont Bioservices Recent Developments
- 12.14 VectorBuilder
- 12.14.1 VectorBuilder Company Information
- 12.14.2 VectorBuilder Business Overview
- 12.14.3 VectorBuilder Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.14.4 VectorBuilder Advanced Biopharmaceutical Therapies Product Portfolio
- 12.14.5 VectorBuilder Recent Developments
- 12.15 Viralgen
- 12.15.1 Viralgen Company Information
- 12.15.2 Viralgen Business Overview
- 12.15.3 Viralgen Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.15.4 Viralgen Advanced Biopharmaceutical Therapies Product Portfolio
- 12.15.5 Viralgen Recent Developments
- 12.16 ABL Europe
- 12.16.1 ABL Europe Company Information
- 12.16.2 ABL Europe Business Overview
- 12.16.3 ABL Europe Revenue in Advanced Biopharmaceutical Therapies Business (2021-2026)
- 12.16.4 ABL Europe Advanced Biopharmaceutical Therapies Product Portfolio
- 12.16.5 ABL Europe Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst